1. Consulting Overview & Global PIC/S Regulatory Framework
Our dedicated PIC/S compliance consulting delivers full-lifecycle, biomanufacturing-specific regulatory advisory services aligned with all core PIC/S harmonized GMP guidelines, including the newly revised PI 006-4 Qualification & Validation (effective Oct 1, 2026), PE 009-17 Sterile Manufacturing Annex 1, PI 041 Data Integrity, PI 043 Advanced Therapy Medicinal Products and PIC/S Annex 2 Biological Manufacturing guidance. The service covers greenfield plant conceptual design, brownfield facility gap remediation, clinical pilot suites, ADC high-potency workshops, recombinant protein and viral vector production facilities for cross-border biotech developers, CMOs and pharmaceutical groups targeting PIC/S member-state markets across Asia, the Middle East, Europe and Africa.
Unlike generic GMP consulting that only addresses local national codes, our PIC/S-centric advisory resolves core cross-border compliance pain points: misalignment of facility layout with PIC/S contamination control mandates, outdated lifecycle validation strategies failing PI 006-4 revised rules, incomplete data integrity governance, unstructured quality risk management (QRM) and inadequate audit-ready technical documentation. We provide end-to-end gap analysis, design guidance, validation master planning and pre-inspection simulation to help biomanufacturing facilities pass official PIC/S joint inspectorate audits and support global drug registration filings.
2. Core Consulting Philosophy & PIC/S Compliance Advantages
1.Harmonized dual-standard alignment
All facility and process recommendations simultaneously satisfy PIC/S harmonized GMP plus host-country national pharmaceutical legislation, eliminating costly redesign or validation rework during local PIC/S authority inspections; our team maps all PIC/S Annex and PI document clauses against bioprocess workflows for mAbs, recombinant proteins, ADCs and viral therapeutics.
2.Front-end design compliance embedding
We integrate PIC/S layout requirements at the conceptual design phase: graded cleanroom zoning, unidirectional personnel/material/waste flow, negative-pressure containment for cytotoxic payload zones, dedicated isolated CIP/SIP loops and HVAC pressure cascade systems to meet PE 009-17 Annex 1 contamination control strategy (CCS) obligations.
3.PI 006-4 updated validation system implementation
We phase out obsolete retrospective validation, restructure full CQV workflows around pre-qualification, staged PQ and ongoing process verification, and design HBEL-based cleaning validation protocols fully compliant with the 2026 revised PIC/S validation standard.
3.Complete audit traceability documentation architecture
We build unified PIC/S-compliant document hierarchies including validation master plans, facility FMEA risk assessments, electronic batch recording frameworks and CAPA closed-loop systems, addressing data integrity non-conformities — the top inspection observation across PIC/S global audits.
Compared with region-only compliance consultants, our PIC/S specialist team delivers consistent inspection readiness across all member jurisdictions and reduces major audit deviation risks by standardizing facility, process and quality system controls against unified international inspector benchmarks.
3. Four Integrated PIC/S Consulting Core Modules & Standard Deliverables
Module 1: Pre-project PIC/S Gap & Design Consultancy
Module 2: Facility & Equipment CQV Advisory (PI 006-4 Compliant)
Module 3: QMS PIC/S Alignment Module
Module 4: Pre-inspection Audit Preparation & Remediation
4. Industrial Application & Full Lifecycle Continuous Compliance Support
Our PIC/S standards consulting services apply to new commercial biologic greenfield manufacturing campuses, legacy biopharma plant GMP retrofits, clinical-stage pilot bioprocessing suites, high-containment ADC and viral vector production facilities, and multi-product flexible CMO manufacturing bases exporting to PIC/S member territories. All PIC/S compliance frameworks adopt modular scalable structures, allowing clients to expand production lines or launch new therapeutic pipelines without full-scale QMS or validation overhauls.
We provide long-term post-handover continuous compliance services including annual PIC/S regulation update training, periodic facility compliance re-assessment, change control risk re-evaluation for process/equipment upgrades, and remote technical advisory for routine inspector follow-up requests. By embedding unified PIC/S harmonized GMP standards into every facility design, validation and quality management activity, our consulting service eliminates cross-border regulatory compliance barriers, shortens global drug registration timelines and enables biopharmaceutical manufacturers to maintain sustained inspection readiness for international PIC/S regulatory authorities.
